Prostate cancer in African-American men appears to be associated with specific changes in the IL-16 gene, according to researchers at the University of Illinois at Chicago College of Medicine.
Prostate cancer in African-American men appears to be associated with specific changes in the IL-16 gene, according to researchers at the University of Illinois at Chicago College of Medicine.
The researchers say their study, which was published online in Cancer Epidemiology, Biomarkers & Prevention (Aug. 24, 2012), establishes the association of IL-16 with prostate cancer in men of both African and European descent.
"This provides us with a new potential biomarker for prostate cancer," said principal investigator Rick Kittles, PhD.
Dr. Kittles and his colleagues used imputation to see new patterns of association and identify new places in the gene to look for polymorphisms. They found changes elsewhere in the IL-16 gene that were associated with prostate cancer and that were unique to African-Americans.
Although the effect of the particular changes to the gene appear to be different in men of African versus European descent, it is likely that several of the polymorphisms in the gene alter the function of the IL-16 protein.
"This confirms the importance of IL-16 in prostate cancer and leads us in a new direction," Dr. Kittles said. "Very little research has been done on IL-16, so not much is known about it. We now need to explore the functional role of IL-16 to understand the role it is playing in prostate cancer."
Go back to this issue of Urology Times eNews.
Related Content
AUA, SUFU publish 2024 guideline for idiopathic overactive bladder
April 25th 2024“This brand new guideline offers options for all patients with OAB with a focus on shared decision-making between patients with OAB and clinicians, as well as a personalized, tailored approach to care,” said Cameron and Smith.
Enzalutamide granted approval in EU for nmHSPC
April 24th 2024The approval is supported by data from the phase 3 EMBARK trial, which demonstrated that enzalutamide with or without leuprolide prolonged metastasis-free survival compared with leuprolide alone in patients with high-risk biochemically recurrent nmHSPC.